Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5203_Библиотеки_им_академика_М_И_Перельмана.pdf
310
480. Leung E, Ngo DH, Espinoza JA Jr, etal. A retrospective study of the adjunctive use of gabapentin with benzodiazepines for the treatment of benzodiazepine withdrawal. J Psychiatr
Pract. 2022;28(4):310–8.
481. Wu B, Cao Y, Meng M, etal. Gabapentin alleviates myocardial ischemia-reperfusion injury
by increasing the protein expression of GABA(A)Rδ. Eur J Pharmacol. 2023;944:175585.
482. Shen Y, Li W, Ma M, etal. Efcacy and safety of gabapentin in improving sleep quality of
patients with sensory nervous system diseases: a meta-analysis. Altern Ther Health Med.
2023;29(5):380–5.
483. Zhao T, Feng X, Liu J, etal. Evaluate the efcacy and safety of anti-epileptic medications for
partial seizures of epilepsy: a network meta-analysis. J Cell Biochem. 2017;118(9):2850–64.
484. French J, Kwan P, Fakhoury T, etal. Pregabalin monotherapy in patients with partial-onset
seizures: a historical-controlled trial. Neurology. 2014;82(7):590–7.
485. Kwan P, Brodie MJ, Kälviäinen R, etal. Efcacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised,
parallel- group trial. Lancet Neurol. 2011;10(10):881–90.
486. de Bruin ME, van der Meer PB, Dirven L, etal. Efcacy of antiepileptic drugs in glioma
patients with epilepsy: a systematic review. Neurooncol Pract. 2021;8(5):501–17.
487. Driscoll J, Almas M, Gregorian G, etal. Pregabalin as adjunctive therapy in adult and pediatric patients with generalized tonic-clonic seizures: a randomized, placebo-controlled trial.
Epilepsia Open. 2021;6(2):381–93.
488. Kanner AM, Ashman E, Gloss D, etal. Practice guideline update summary: efcacy and
tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the
Guideline Development, Dissemination, and Implementation Subcommittee of the American
Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):82–90.
489. Panebianco M, Bresnahan R, Hemming K, etal. Pregabalin add-on for drug-resistant focal
epilepsy. Cochrane Database Syst Rev. 2019;7(7):CD005612.
490. Panebianco M, Bresnahan R, Marson AG.Pregabalin add-on for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2022;3(3):CD005612.
491. Viteva E, Zahariev Z.Comparative effectiveness of add-on therapy with newer- generation
antiepileptic drugs in Bulgarian patients with refractory epilepsy. Epilepsy Behav.
2018;87:137–45.
492. Androsova G, Krause R, Borghei M, etal. Comparative effectiveness of antiepileptic drugs
in patients with mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia.
2017;58(10):1734–41.
493. Ochoa JG, Dougherty M, Papanastassiou A, etal. Treatment of super-refractory status epilepticus: a review. Epilepsy Curr. 2021;21(6):1535759721999670.
494. Gomes D, Pimentel J, Bentes C, etal. Consensus protocol for the treatment of super- refractory
status epilepticus. Acta Med Port. 2018;31(10):598–605.
495. Novy J, Rossetti AO.Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia.
2010;51(10):2207–10.
496. Swisher CB, Doreswamy M, Gingrich KJ, etal. Phenytoin, levetiracetam, and pregabalin in
the acute management of refractory status epilepticus in patients with brain tumors. Neurocrit
Care. 2012;16(1):109–13.
497. Swisher CB, Doreswamy M, Husain AM.Use of pregabalin for nonconvulsive seizures and
nonconvulsive status epilepticus. Seizure. 2013;22(2):116–8.
498. Mann D, Antinew J, Knapp L, etal. Pregabalin adjunctive therapy for focal onset seizures in children 1 month to <4 years of age: a double-blind, placebo-controlled, videoelectroencephalographic trial. Epilepsia. 2020;61(4):617–26.
499. Antinew J, Pitrosky B, Knapp L, etal. Pregabalin as adjunctive treatment for focal onset seizures in pediatric patients: a randomized controlled trial. J Child Neurol. 2019;34(5):248–55.
500. Chan PLS, Marshall SF, McFadyen L, et al. Pregabalin population pharmacokinetic and
exposure-response analyses for focal onset seizures in children (4-16 years) and adults, to
support dose recommendations in children. Clin Pharmacol Ther. 2021;110(1):132–40.
W. Jing et al.
2 Antiseizure Medications
501. Dudukina E, Szépligeti SK, Karlsson P.Prenatal exposure to pregabalin, birth outcomes and
neurodevelopment– a population-based cohort study in four Nordic countries. Drug Saf.
2023;46(7):661–75.
502. Parekh M, Dash GK, Ahamed I.Pregabalin toxicity manifesting as reversible encephalopathy with continuous triphasic waves in electroencephalogram. Clin Neuropharmacol.
2017;40(5):226–8.
503. Anand P, Kaplan PW.Triphasic waves and encephalopathy in the setting of pregabalin toxicity. J Clin Neurophysiol. 2018;35(6):515–7.
504. Cross AL, Viswanath O, Sherman AL.Pregabalin. In: StatPearls. Treasure Island: StatPearls
Publishing; 2024.
505. Baftiu A, Lima MH, Svendsen K, etal. Safety aspects of antiepileptic drugs-a populationbased study of adverse effects relative to changes in utilisation. Eur J Clin Pharmacol.
2019;75(8):1153–60.
506. Prakash S, Rathore C, Rana K, etal. Antiepileptic drugs and serotonin syndrome– a systematic review of case series and case reports. Seizure. 2021;91:117–31.
507. Shukla S, Rastogi S, Abdi SAH, etal. Severe cutaneous adverse reactions in Asians: trends
observed in culprit anti-seizure medicines using VigiBase®. Seizure. 2021;91:332–8.
508. Hamed SA. Sexual dysfunctions induced by pregabalin. Clin Neuropharmacol.
2018;41(4):116–22.
509. da Costa Sobral KG, Neuberger B, Mello FK, etal. Anticonvulsant activity of β-caryophyllene
in association with pregabalin in a seizure model in rats. Epilepsy Res. 2022;179:106842.
510. Qureshi I, Riaz A, Khan R, etal. Effects of pregabalin, nimodipine, and their combination
in the inhibition of status epilepticus and the prevention of death in mice. Turk J Pharm Sci.
2021;18(4):398–404.
511. Imran I, Koch K, Schöfer H, etal. Effects of three antiseizure medications on cholinergic and
metabolic activity in experimental status epilepticus. J Pharm Pharm Sci. 2019;22(1):340–51.
512. Tong C, Zhengyao Z, Mei L, etal. Pregabalin and gabapentin in patients with spinal cord
injury-related neuropathic pain: a network meta-analysis. Pain Ther. 2021;10(2):1497–509.
513. Onakpoya IJ, Thomas ET, Lee JJ, etal. Benets and harms of pregabalin in the management
of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ
Open. 2019;9(1):e023600.
514. Derry S, Bell RF, Straube S, etal. Pregabalin for neuropathic pain in adults. Cochrane
Database Syst Rev. 2019;1(1):CD007076.
515. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological
disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
Lancet Neurol. 2019;18(5):459–80.
516. Kalilani L, Sun X, Pelgrims B, etal. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018;59(12):2179–93.
517. Humayun MJ, Samanta D, Carson RP.Clobazam. In: StatPearls. Treasure Island: StatPearls
Publishing LLC; 2024. Disclosure: Debopam Samanta declares no relevant nancial relationships with ineligible companies. Disclosure: Robert Carson declares no relevant nancial
relationships with ineligible companies.
518. Brahmbhatt N, Stupp R, Bushara O, etal. Efcacy of clobazam as add-on therapy in brain
tumor-related epilepsy. J Neurooncol. 2021;151(2):287–93.
519. Cochrane Central Register of Controlled Trials. Clobazam has equivalent efcacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for
Childhood Epilepsy. Epilepsia. 1998;39(9):952–9.
520. Arya R, Giridharan N, Anand V, etal. Clobazam monotherapy for focal or generalized seizures. Cochrane Database Syst Rev. 2018;7(7):CD009258.
521. Dulac O, Figueroa D, Rey E, etal. [Monotherapy with clobazam in epilepsies in children].
Presse Med. 1983;12(17):1067–9.
522. Mehndiratta MM, Krishnamurthy M, Rajesh KN, etal. Clobazam monotherapy in drug naïve
adult patients with epilepsy. Seizure. 2003;12(4):226–8.
311
312
523. Kamaşak T, Serdaroğlu E, Yılmaz Ö, etal. The effectiveness and tolerability of clobazam in
the pediatric population: adjunctive therapy and monotherapy in a large-cohort multicenter
study. Epilepsy Res. 2022;184:106963.
524. Jamil A, Levinson N, Gelfand M, etal. Efcacy and tolerability of clobazam in adults with
drug-refractory epilepsy. Neurol Clin Pract. 2021;11(5):e669–76.
525. Talwar A, Estes E, Aparasu R, et al. Clinical efcacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis. Exp Neurol.
2023;359:114238.
526. Nagarajan E, Lynch TM, Frawley B, etal. Tolerability of clobazam as add-on therapy in
patients aged 50 years and older with drug-resistant epilepsy. Neurol Sci. 2023;44(8):2883–8.
527. Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the
Canadian experience. A retrospective study. Epilepsia. 1991;32(3):407–16.
528. Kalra V, Seth R, Mishra D, etal. Clobazam in refractory childhood epilepsy. Indian J Pediatr.
2010;77(3):263–6.
529. Maille JM, Hanna SS, Shah DN.Addition of clobazam successfully treating drug resistant
seizures in Heidenhain variant Creutzfeldt Jakob disease: a case report. Epilepsy Behav Rep.
2023;21:100585.
530. Serrano-Castro PJ, Rodríguez-Uranga JJ, Cabezudo-García P, etal. Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with antiGAD65 antibodies. Neurol Neuroimmunol Neuroinamm. 2023;10(6):e200151.
531. Rana RR, Rajasekaran K, Knappertz V, etal. Pharmacodynamic synergism contributes to the
antiseizure action of cannabidiol and clobazam. Exp Neurol. 2023;360:114286.
532. Sharma A, Kumar A.Identication of novel signal of clobazam-associated drug reaction with
eosinophilia and systemic symptoms syndrome: a disproportionality analysis. Acta Neurol
Scand. 2022;146(5):623–7.
533. Zhang JF, Nickerson K, Piryani R, etal. Macroglossia associated with clobazam administration: a case report and literature review. Front Neurol. 2022;13:900763.
534. Kart P, Gürgen SG, Esenülkü G, etal. An investigation of the effects of chronic zonisamide,
sultiam, lacosamide, clobazam, and runamide anti-seizure medications on foliculogenesis
in ovarian tissue in prepubertal non-epileptic rats. Int J Dev Neurosci. 2022;82(5):436–46.
535. Elakkary S, Hagemann A, Klimpel D, etal. A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam. Epilepsia.
2023;64(4):e36–42.
536. Sankar R.GABA(A) receptor physiology and its relationship to the mechanism of action of
the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26(3):229–44.
537. Ng YT, Conry JA, Drummond R, etal. Randomized, phase III study results of clobazam in
Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473–81.
538. Gunning B, Mazurkiewicz-Bełdzińska M, Chin RFM, et al. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurol Scand.
2021;143(2):154–63.
539. Wilensky AJ, Friel PN, Ojemann LM, etal. Pharmacokinetics of W-554 (ADD 03055) in
epileptic patients. Epilepsia. 1985;26(6):602–6.
540. Leppik IE, Dreifuss FE, Pledger GW, etal. Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991;41(11):1785–9.
541. Gasior M, Swiader M, Przybyłko M, etal. Felbamate demonstrates low propensity for interaction with methylxanthines and Ca2+ channel modulators against experimental seizures in
mice. Eur J Pharmacol. 1998;352(2–3):207–14.
542. Borowicz KK, Ratnaraj N, Patsalos PN, etal. Effect of felbamate and its combinations
with conventional antiepileptics in amygdala-kindled rats. Pharmacol Biochem Behav.
2004;78(1):103–10.
543. Heyman E, Levin N, Lahat E, etal. Efcacy and safety of felbamate in children with refractory epilepsy. Eur J Paediatr Neurol. 2014;18(6):658–62.
W. Jing et al.
2 Antiseizure Medications
544. Reed L, Ciliberto M, Fong SL, etal. Efcacy of felbamate in a cohort of patients with epilepsy with myoclonic atonic seizures (EMAtS). Epilepsy Res. 2024;201:107314.
545. Wilcox MA, Hardin J, Weaver J, etal. Liver test monitoring: real-world compliance for drugs
with monitoring requirements at 2-week intervals or more frequently. Pharmaceut Med.
2019;33(5):389–94.
546. Felbamate Study Group in Lennox-Gastaut Syndrome. Efcacy of felbamate in childhood
epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328(1):29–33.
547. Shi LL, Dong J, Ni H, etal. Felbamate as an add-on therapy for refractory partial epilepsy.
Cochrane Database Syst Rev. 2017;7(7):CD008295.
548. Strzelczyk A, Schubert-Bast S.Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies. CNS Drugs. 2021;35(1):61–83.
549. Mazarati AM, Baldwin RA, Soa RD, etal. Felbamate in experimental model of status epilepticus. Epilepsia. 2000;41(2):123–7.
550. Yerby MS, McCoy GB. Male infertility: possible association with valproate exposure.
Epilepsia. 1999;40(4):520–1.
551. Mishal NM, Arkilo D, Tang J, etal. A potential role for Felbamate in TSC- and NF1-related
epilepsy: a case report and review of the literature. Case Rep Neurol Med. 2015;2015:960746.
552. Rabinowicz S, Schreiber T, Heimer G, etal. Felbamate for pediatric epilepsy-should we keep
on using it as the last resort? Front Neurol. 2022;13:979725.
553. Hussain SA, Asilnejad B, Heesch J, etal. Felbamate in the treatment of refractory epileptic
spasms. Epilepsy Res. 2020;161:106284.
554. Dozières-Puyravel B, Nasser H, Bellavoine V, etal. Felbamate for infantile spasms syndrome
resistant to rst-line treatments. Dev Med Child Neurol. 2020;62(5):581–6.
555. de Jong J, Garne E, de Jong-van den Berg LT, etal. The risk of specic congenital anomalies
in relation to newer antiepileptic drugs: a literature review. Drugs Real World Outcomes.
2016;3(2):131–43.
556. Shi LL, Bresnahan R, Martin-McGill KJ, etal. Felbamate add-on therapy for drug-resistant
focal epilepsy. Cochrane Database Syst Rev. 2022;8(8):CD008295.
557. Devi N, Madaan P, Ameen R, etal. Short-term and long-term efcacy and safety of antiseizure medications in Lennox Gastaut syndrome: a network meta-analysis. Seizure.
2022;99:164–75.
558. Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol.
2017;77:23–36.
559. Jacob S, Nair AB.An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs R&D. 2016;16(4):303–16.
560. Celli R, Fornai F.Targeting ionotropic glutamate receptors in the treatment of epilepsy. Curr
Neuropharmacol. 2021;19(6):747–65.
561. Li X, Wang H, Chen Q, etal. Felbamate produces antidepressant-like actions in the chronic
unpredictable mild stress and chronic social defeat stress models of depression. Fundam Clin
Pharmacol. 2019;33(6):621–33.
562. Bayhan I, Turtay MG, Ciftci O, etal. Comparison of immunological, histological and oxidative effects of felbamate and levetiracetam in traumatic brain injury. Eur Rev Med Pharmacol
Sci. 2020;24(12):7083–91.
563. Schechter PJ, Tranier Y. Effect of GABA-transminase inhibition on rectal temperature in
mice. Pharmacol Biochem Behav. 1977;6(6):667–9.
564. Gale K, Iadarola MJ.Seizure protection and increased nerve-terminal GABA: delayed effects
of GABA transaminase inhibition. Science (New York, NY). 1980;208(4441):288–91.
565. Gale K, Iadarola M.Drug-induced elevation of GABA after intracerebral microinjection: site
of anticonvulsant action. Eur J Pharmacol. 1980;68(2):233–5.
566. Kalichman MW, Livingston KE, Burnham WM.Pharmacological investigation of gamma
aminobutyric acid (GABA) and the development of amygdala-kindled seizures in the rat. Exp
Neurol. 1981;74(3):829–36.
313
314
567. Gram L, Lyon BB, Dam M.Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy. Acta Neurol Scand. 1983;68(1):34–9.
568. Tierradentro-García LO, Zandifar A, Stern J, etal. Magnetic resonance imaging-based distribution and reversibility of lesions in pediatric vigabatrin-related brain toxicity. Pediatr
Neurol. 2023;148:86–93.
569. Kuchenbuch M, Lo Barco T, Chemaly N, et al. Fifteen years of real-world data on the
use of vigabatrin in individuals with infantile epileptic spasms syndrome. Epilepsia.
2024;65(2):430–44.
570. Grinspan ZM, Knupp KG, Patel AD, etal. Comparative effectiveness of initial treatment for
infantile spasms in a contemporary US cohort. Neurology. 2021;97(12):e1217–e28.
571. Gatson TN, Freemont OA, Coleman RL, etal. Vigabatrin (Sabril) for the treatment of refractory complex focal seizures in adults: pharmacologic and clinical considerations. Cureus.
2023;15(10):e46414.
572. Sharma S, Kaushik JS, Srivastava K, etal. Association of Child Neurology (AOCN)– Indian
Epilepsy Society (IES) consensus guidelines for the diagnosis and management of West syndrome. Indian Pediatr. 2021;58(1):54–66.
573. Ramantani G, Bölsterli BK, Alber M, etal. Treatment of infantile spasm syndrome: update
from the Interdisciplinary Guideline Committee coordinated by the German-Speaking
Society of Neuropediatrics. Neuropediatrics. 2022;53(6):389–401.
574. Xu Z, Gong P, Jiao X, etal. Efcacy of vigabatrin in the treatment of infantile epileptic spasms
syndrome: a systematic review and meta-analysis. Epilepsia Open. 2023;8(2):268–77.
575. Kotulska K, Kwiatkowski DJ, Curatolo P, etal. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol. 2021;89(2):304–14.
576. Lin S, Liao J, Zhao X, etal. Focal epilepsy in children with tuberous sclerosis complex: does
vigabatrin control focal seizures? J Child Neurol. 2022;37(5):329–33.
577. Sakpichaisakul K, Boonkrongsak R, Lertbutsayanukul P, et al. Epileptic spasms related to
neuronal differentiation factor 2 (NEUROD2) mutation respond to combined vigabatrin and
high dose prednisolone therapy. BMC Neurol. 2022;22(1):461.
578. Datta AN, Crawford J, Wong PKH.Infantile spasms and trisomy 21: unfavorable outcomes
with rst-line vigabatrin therapy. Can J Neurol Sci. 2021;48(6):839–44.
579. Wan L, Li Z, Sun Y, etal. Clinical characteristics and treatment outcomes of pediatric patients
with postencephalitic epilepsy characterized by epileptic spasms. Seizure. 2021;84:116–21.
580. Saleh DA, Hassan A.Clinical prole, treatment modalities, and outcomes in patients with
infantile spasms: a retrospective study from the United Arab of Emirates (UAE). Epilepsy
Behav. 2022;127:108519.
581. Bashiri FA, Al-Sehemi MA, Hamad MH, etal. Neurodevelopmental and epilepsy outcomes
of patients with infantile spasms treated in a tertiary care center. Neurosciences (Riyadh).
2021;26(1):21–5.
582. Kuchenbuch M, Chiron C, Milh M. Overview of therapeutic options for epilepsy. Arch
Pediatr. 2022;29(5S):5S14–5S9.
583. Golec W, Sołowiej E, Strzelecka J, etal. Vigabatrin– new data on indications and safety in
paediatric epilepsy. Neurol Neurochir Pol. 2021;55(5):429–39.
584. Desnous B, Lenoir M, Bitton JY, et al. What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer? Seizure. 2021;91:503–6.
585. Leppien EE, Doughty BJ, Hurd KL, etal. Newer antiseizure medications and suicidality:
analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS)
database. Clin Drug Investig. 2023;43(6):393–9.
586. Prezioso G, Chiarelli F, Matricardi S.Efcacy and safety of vigabatrin in patients with tuberous sclerosis complex and infantile epileptic spasm syndrome: a systematic review. Expert
Rev Neurother. 2023;23(7):661–71.
587. Lai MC, Huang CW.The discordance between network excitability and cognitive performance following vigabatrin treatment during epileptogenesis. Life (Basel). 2021;11(11):1213.
W. Jing et al.
2 Antiseizure Medications
588. Ikeda A, Tomiyasu M, Yamamoto A, etal. Elevation of brain gamma-aminobutyric acid levels
is associated with vigabatrin-associated brain abnormalities on magnetic resonance imaging.
Epilepsy Res. 2022;181:106881.
589. Reyes Valenzuela G, Crespo A, Princich J, etal. Vigabatrin-associated brain abnormalities
on MRI and other neurological symptoms in patients with West syndrome. Epilepsy Behav.
2022;129:108606.
590. Harini C, Yuskaitis CJ, Libenson MH, et al. Hippocampal involvement with vigabatrinrelated MRI signal abnormalities in patients with infantile spasms: a novel nding. J Child
Neurol. 2021;36(7):575–82.
591. Xu Y, Wan L, He W, etal. Risk of vigabatrin-associated brain abnormalities on MRI: a retrospective and controlled study. Epilepsia. 2022;63(1):120–9.
592. Craft JF, Cardenas AM.Vigabatrin-associated reversible MRI abnormalities in an infant with
tuberous sclerosis. J Radiol Case Rep. 2021;15(2):1–6.
593. Jonsson H, Lehto M, Vanhatalo S, etal. Visual eld defects after vigabatrin treatment during
infancy: retrospective population-based study. Dev Med Child Neurol. 2022;64(5):641–8.
594. Giuliano L, Vecchio C, Mastrangelo V, et al. Sex differences in side effects of antiseizure
medications in pediatric patients with epilepsy: a systematic review. Seizure. 2022;102:6–13.
595. Abd El-Kader M, Hamza E, El-Gamal R, etal. Modulation of vigabatrin induced cerebellar
injury: the role of caspase-3 and RIPK1/RIPK3-regulated cell death pathways. J Mol Histol.
2021;52(4):781–98.
596. Walters DC, Jansen EEW, Salomons GS, etal. Preferential accumulation of the active S-(+)
isomer in murine retina highlights novel mechanisms of vigabatrin-associated retinal toxicity.
Epilepsy Res. 2021;170:106536.
597. Hung TY, Huang HI, Wu SN, etal. Depressive effectiveness of vigabatrin (γ-vinyl-GABA),
an antiepileptic drug, in intermediate-conductance calcium-activated potassium channels in
human glioma cells. BMC Pharmacol Toxicol. 2021;22(1):6.
598. Jin P, You YX, Zhao LL, etal. A simple and easy non-derivatization gas chromatographymass spectrometry method for simultaneous quantication of valproic acid, gabapentin, pregabalin, and vigabatrin in human plasma. J Sep Sci. 2023;46(2):e2200622.
599. Wang J, Zhang YY, Guo HL, etal. Rapid determination of plasma vigabatrin by LC-ESI-MS/
MS supporting therapeutic drug monitoring in children with infantile spasms. Anal Methods.
2023;15(10):1365–77.
600. Ito T, Hori M, Masuda Y, etal. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Electroencephalographic prole. Arzneimittelforschung. 1980;30(4):603–9.
601. Sackellares JC, Donofrio PD, Wagner JG, et al. Pilot study of zonisamide (1,2- benzis
oxazole- 3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia.
1985;26(3):206–11.
602. Hammond EJ, Perchalski RJ, Wilder BJ, etal. Neuropharmacology of zonisamide, a new
antiepileptic drug. Gen Pharmacol. 1987;18(3):303–7.
603. Tousi B, Leverenz JB.The application of zonisamide to patients suffering from dementia
with Lewy bodies: emerging clinical data. Drug Des Devel Ther. 2021;15:1811–7.
604. Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by
zonisamide. Seizure. 1996;5(2):115–9.
605. Aslan M, Gungor S.Effectiveness of zonisamide in childhood refractory epilepsy. Childs
Nerv Syst. 2022;38(5):971–6.
606. Brodie MJ. Zonisamide clinical trials: European experience. Seizure. 2004;13(Suppl
1):S66–70; discussion S1–2.
607. Tsujii S, Ishisaka M, Shimazawa M, etal. Zonisamide suppresses endoplasmic reticulum
stress-induced neuronal cell damage invitro and invivo. Eur J Pharmacol. 2015;746:301–7.
608. Parravicini S, Pasca L, Zanaboni MP, et al. Electroclinical improvement in a patient with
ring chromosome 20 syndrome treated with zonisamide: a case report. J Pediatr Genet.
2023;12(3):219–23.
315
316
609. Rubio-Nazábal E, Álvarez-Pérez P, Cores-Bartolomé C, et al. [Efcacy of zonisamide in
Lafora’s disease case and brief review of its use in progressive myoclonic epilepsy]. Rev
Neurol. 2022;75(6):159–63.
610. McCluskey G, Kinney MO, Russell A, etal. Zonisamide safety in pregnancy: data from the
UK and Ireland epilepsy and pregnancy register. Seizure. 2021;91:311–5.
611. Herzog R, Hellenbroich Y, Brüggemann N, et al. Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy. Ann Clin Transl Neurol.
2021;8(7):1524–7.
612. Huang CR, Chuang HY, Chen NC, et al. Zonisamide therapy reduces metabolic consequences and diminishes nonalcoholic fatty liver disease in patients with epilepsy. J Clin Med.
2021;10(15):3380.
613. Naito T, Satake W, Cha PC, et al. Comparative whole transcriptome analysis of
Parkinson’s disease focusing on the efcacy of zonisamide. J Neurol Neurosurg Psychiatry.
2022;93(5):509–12.
614. Suzuki K, Fujita H, Matsubara T, etal. Zonisamide effects on sleep problems and depressive
symptoms in Parkinson’s disease. Brain Behav. 2021;11(3):e02026.
615. Hasegawa K, Kochi K, Maruyama H, etal. Efcacy and safety of zonisamide in dementia with Lewy bodies patients with parkinsonism: a post hoc analysis of two randomized,
double-blind, placebo-controlled trials. J Alzheimers Dis. 2021;79(2):627–37.
616. Ikeda M, Mori E, Orimo S, etal. Efcacy of adjunctive therapy with zonisamide versus
increased dose of levodopa for motor symptoms in patients with dementia with Lewy
bodies: the randomized, controlled, non-inferiority DUEL study. J Alzheimers Dis.
2023;95(1):251–64.
617. Kong L, Xi J, Jiang Z, etal. Zonisamide’s efcacy and safety on Parkinson’s disease and
dementia with Lewy bodies: a meta-analysis and systematic review. Biomed Res Int.
2022;2022:4817488.
618. Tada S, Choudhury ME, Kubo M, etal. Zonisamide ameliorates microglial mitochondriopathy in Parkinson’s disease models. Brain Sci. 2022;12(2):268.
619. Rose JE, Willette PN, Botts TL, etal. Bupropion/zonisamide combination to assist smokers
to switch from combustible cigarettes to electronic nicotine delivery systems (ENDS). Drug
Alcohol Depend. 2022;234:109346.
620. Reinfeld S, Tejeda CI, Koola MM.Delirium in the context of zonisamide-induced toxic epidermal necrolysis. Prim Care Companion CNS Disord. 2022;24(1):21cr03108.
621. MacMahon T, Kelly YP.Zonisamide-induced distal renal tubular acidosis and critical hypokalaemia. BMJ Case Rep. 2023;16(4):e254615.
622. Panda PK, Sharawat IK, Panda P, etal. Efcacy, tolerability, and safety of zonisamide in children with epileptic spasms: a systematic review and meta-analysis. Seizure. 2021;91:374–83.
623. Inoue T, Ohkawara B, Bushra S, et al. Zonisamide upregulates neuregulin-1 expression
and enhances acetylcholine receptor clustering at the in vitro neuromuscular junction.
Neuropharmacology. 2021;195:108637.
624. Takaku S, Sango K.Pretreatment with zonisamide mitigates oxaliplatin-induced toxicity in rat
DRG neurons and DRG neuron-Schwann cell co-cultures. Int J Mol Sci. 2022;23(17):9983.
625. Ismail FS, Faustmann PM, Förster E, etal. Tiagabine and zonisamide differentially regulate the glial properties in an astrocyte-microglia co-culture model of inammation. Naunyn
Schmiedeberg’s Arch Pharmacol. 2023;396(11):3253–67.
626. Nakatsuka K, Zanghi B, Hasegawa D.Efcacy evaluation of a commercially available MCT
enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary
study. BMC Vet Res. 2023;19(1):145.
627. Shorvon S, Perucca E, Jerome E Jr. The treatment of epilepsy. 4th ed. Wiley-Blackwell; 2016.
628. Li J, Sun M, Wang X. The adverse-effect prole of lacosamide. Expert Opin Drug Saf.
2020;19(2):131–8.
W. Jing et al.
2 Antiseizure Medications
629. Inoue Y, Liao W, Wang X, etal. Safety and efcacy of adjunctive lacosamide in Chinese
and Japanese adults with epilepsy and focal seizures: a long-term, open-label extension of a
randomized, controlled trial. Epilepsy Res. 2021;176:106705.
630. Baulac M, Rosenow F, Toledo M, etal. Efcacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy:
a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017;16(1):43–54.
631. Vossler DG, Knake S, O’Brien TJ, etal. Efcacy and safety of adjunctive lacosamide in the
treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebocontrolled trial. J Neurol Neurosurg Psychiatry. 2020;91(10):1067–75.
632. Lazzarotto L, Püger P, Regner GG, etal. Lacosamide improves biochemical, genotoxic,
and mitochondrial parameters after PTZ-kindling model in mice. Fundam Clin Pharmacol.
2021;35(2):351–63.
633. Bilal B, Kirazlar M, Erdogan MA, etal. Lacosamide exhibits neuroprotective effects in a rat
model of Parkinson’s disease. J Chem Neuroanat. 2023;132:102311.
634. Langton RL, Sharma S, Tiarks GC, etal. Lacosamide decreases neonatal seizures without
increasing apoptosis. Epilepsia. 2022;63(12):3051–65.
635. Agarwal S, Vyas P, Nirwan N, etal. Effect of lacosamide on neuroinammation-mediated
seizures comorbid with depression in C57BL/6 mice- role of kynurenine pathway. Epilepsy
Behav. 2021;123:108262.
636. Corvace F, Faustmann TJ, Faustmann PM, etal. Anti-inammatory properties of lacosamide in an astrocyte-microglia co-culture model of inammation. Eur J Pharmacol.
2022;915:174696.
637. Szewczyk A, Zagaja M, Szala-Rycaj J, etal. Effect of lacosamide and ethosuximide chronic
treatment on neural precursor cells and cognitive functions after pilocarpine induced status
epilepticus in mice. Brain Sci. 2021;11(8):1014.
638. Sumbul O, Aygun H. Electrocorticographic and electrocardiographic evaluation of lacosamide in a penicillin-induced status epilepticus model. Epilepsy Res. 2022;180:106866.
639. Wu PM, Lin YC, Chiang CW, etal. Effective modulation by lacosamide on cumulative inhibition of I(Na) during high-frequency stimulation and recovery of I(Na) block during conditioning pulse train. Int J Mol Sci. 2022;23(19):11966.
640. Messahel S, Bracken L, Appleton R.Optimal management of status epilepticus in children in the emergency setting: a review of recent advances. Open Access Emerg Med.
2022;14:491–506.
641. Schaidle S, Greathouse K, McConnell D.Safety and efcacy of lacosamide versus phenytoin
for refractory seizures in neurosurgical patients. BMJ Neurol Open. 2021;3(1):e000144.
642. Rollo E, Romozzi M, Dono F, etal. Treatment of benzodiazepine-refractory status epilepticus: a retrospective, cohort study. Epilepsy Behav. 2023;140:109093.
643. Chimakurthy AK, Ramsay RE, Sabharwal V, etal. Safety, tolerability, and pharmacokinetics
of weight-based IV loading dose of lacosamide in the ICU.Epilepsy Behav. 2021;114(Pt
A):107449.
644. Eilam A, Khmeliov N, Penker D, etal. Intravenous lacosamide in seizure clusters: dose and
efcacy. Clin Neuropharmacol. 2021;44(3):85–8.
645. Torian SC, Jones GM. Safety prole of high-dose intravenous push lacosamide.
Neurohospitalist. 2023;13(3):278–82.
646. Kim HK, Lee H, Bae EK, etal. Cardiac effects of rapid intravenous loading of lacosamide in
patients with epilepsy. Epilepsy Res. 2021;176:106710.
647. Fong SL, Utidjian L, Kaur M, etal. Safety of intravenous lacosamide in hospitalized children
and neonates. Epilepsia. 2023;64(9):2297–309.
648. Ragoonanan D, Tran N, Levesque M.Safety and tolerability of intravenous push lacosamide
and levetiracetam. J Pharm Pract. 2023;36(5):1056–60.
649. Gonçalves J, Alves G, Fonseca C, etal. Is intranasal administration an opportunity for direct
brain delivery of lacosamide? Eur J Pharm Sci. 2021;157:105632.
317
318
650. Mo F, Meletti S, Belcastro V, etal. Lacosamide in monotherapy in BTRE (brain tumorrelated epilepsy): results from an Italian multicenter retrospective study. J Neurooncol.
2022;157(3):551–9.
651. Winter Y, Uphaus T, Sandner K, etal. Efcacy and safety of antiseizure medication in poststroke epilepsy. Seizure. 2022;100:109–14.
652. Sharawat IK, Panda PK, Kumar V, etal. Comparative efcacy and safety of lacosamide and
oxcarbazepine for seizure control in children with newly diagnosed solitary neurocysticercosis. J Trop Pediatr. 2022;68(3):fmac032.
653. Okanishi T, Fujii Y, Sakuma S, etal. Lacosamide monotherapy for the treatment of childhood
epilepsy with centrotemporal spikes. Brain Dev. 2022;44(6):380–5.
654. Numoto S, Kurahashi H, Takagi M, etal. Sodium channel blockers are effective for benign
infantile epilepsy. Seizure. 2021;92:207–10.
655. Kobayashi Y, Honda R, Yamada K, etal. Two-year efcacy of lacosamide as adjunctive therapy for generalized tonic-clonic seizures in patients with juvenile myoclonic epilepsy. Brain
Dev. 2023;45(8):451–5.
656. Zawar I, Franic L, Knight EP.Response to lacosamide monotherapy in a patient with medically refractory Jeavons syndrome: a case report and review of the literature. Epileptic
Disord. 2020;22(5):643–7.
657. Goldschagg N, Brem C, Strupp M. Case report: bitter vertigo. Front Neurol.
2022;13:1028597.
658. Masrour S.Lacosamide for refractory trigeminal neuralgia and other facial pain-case report.
Headache. 2022;62(9):1227–30.
659. Muñoz-Vendrell A, Tena-Cucala R, Campoy S, et al. Oral lacosamide for the treatment of refractory trigeminal neuralgia: a retrospective analysis of 86 cases. Headache.
2023;63(4):559–64.
660. Geng JH, Zheng Y, Li QF, etal. Case report: a case of concomitant paroxysmal kinesigenic
dyskinesia and epilepsy: can we treat two birds with one stone? Front Neurol. 2022;13:826897.
661. Fitouchi S, Jesel L, Hirsch E, etal. Epileptic seizure-induced syncopal asystole reversed by
lacosamide: a case report. Europace. 2023;25(4):1510.
662. Ono-Takiguchi Y, Muramatsu K, Koshu K, etal. Forced normalization of Lennox-Gastaut
syndrome using lacosamide: a case report. Brain Dev. 2021;43(9):963–6.
663. Kubo T, Sogawa R, Tsuruhashi S, et al. Risk of delirium with antiepileptic drug use:
a study based on the Japanese Adverse Drug Event Report database. Int J Clin Pharm.
2023;45(5):1260–6.
664. Hamard J, Rigal M, Gony M, etal. Lacosamide-induced personality changes: an unexpected
adverse effect. Fundam Clin Pharmacol. 2022;36(1):224–6.
665. Kawai M, Goji H, Kanemoto K.Aggression as psychiatric side effect of newer AEDs in
patients with epilepsy: cross-sectional study based on Buss-Perry Aggression Questionnaire.
Epilepsy Behav. 2021;115:107546.
666. Matsunuma S, Sunaga S, Hoshiai A, etal. Psychiatric disorders of the combination of levetiracetam either with lacosamide or perampanel: a retrospective cohort study. Int J Clin Pharm.
2021;43(6):1516–22.
667. Goodnough R, Badea A, Geier C, etal. Lacosamide induced Brugada I morphology in the
setting of septicemia: a case report. Medicine (Baltimore). 2021;100(18):e25577.
668. Lu YT, Lin CH, Ho CJ, etal. Evaluation of cardiovascular concerns of intravenous lacosamide therapy in epilepsy patients. Front Neurol. 2022;13:891368.
669. Takai C, Misumi K, Kaito D, etal. Lacosamide intoxication-induced wide QRS tachycardia
successfully treated with veno-arterial extracorporeal membrane oxygenation. Intern Med.
2023;62(8):1185–9.
670. Shibata M, Hoshino R, Shimizu C, etal. Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis. BMC Neurol. 2021;21(1):217.
671. Zhao X, Liu Y, Xu Z. A paediatric case of lacosamide-induced panniculitis. Australas J
Dermatol. 2022;63(1):e107–e9.
W. Jing et al.
2 Antiseizure Medications
672. Tateishi Y, Ishikawa N, Kobayashi Y, etal. Effect of lacosamide therapy on blood cells and
IgA levels in children and adolescents with epilepsy in a clinical setting. Epilepsy Res.
2022;187:107030.
673. Li Y, Guo HL, Zhang YY, et al. Plasma lacosamide monitoring in children with epilepsy:
focus on reference therapeutic range and inuencing factors. Front Pediatr. 2022;10:949783.
674. Zhao T, Li HJ, Zhang HL, etal. Therapeutic drug monitoring of lacosamide in Chinese pediatric patients with epilepsy: efcacy and factors inuencing the plasma concentration. Eur J
Drug Metab Pharmacokinet. 2023;48(1):41–9.
675. Pozzi M, Zanotta N, Epifanio R, etal. Lacosamide effectiveness and tolerability in patients
with drug-resistant epilepsy and severe disability under polytherapy: therapy optimization as
emerging from an observational study. Epilepsy Behav. 2022;128:108598.
676. Ishikawa N, Eguchi Y, Izumo H, etal. Clinical impact of the dose and blood concentration
of lacosamide in Japanese pediatric patients with epilepsy: a cohort study. Epilepsy Behav.
2022;129:108614.
677. Lukka PB, Woods M, Chhim R, etal. Use of real-world data and pharmacometric modeling
in support of lacosamide dosing in pediatric patients under 4 years of age. J Clin Pharmacol.
2021;61(7):881–8.
678. Pennell PB, Karanam A, Meador KJ, etal. Antiseizure medication concentrations during
pregnancy: results from the maternal outcomes and neurodevelopmental effects of antiepileptic drugs (MONEAD) study. JAMA Neurol. 2022;79(4):370–9.
679. Zutshi D, Millis SR, Basha MM, etal. Lacosamide serum concentrations during pregnancy.
Epilepsy Behav. 2021;123:108253.
680. Zhao T, Li HJ, Zhang HL, etal. Impact of ABCC2 1249G>A and −24C>T polymorphisms
on lacosamide efcacy and plasma concentrations in uygur pediatric patients with epilepsy
in China. Ther Drug Monit. 2023;45(1):117–25.
681. Ahn SJ, Oh J, Kim DY, etal. Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy. Epilepsia. 2022;63(11):2958–69.
682. Farkas MK, Beller C, Bozorg A, et al. Safety and tolerability of short-term infusions of
intravenous lacosamide in pediatric patients with epilepsy: an open-label, phase 2/3 trial.
Epilepsia Open. 2023;8(1):146–53.
683. Hoeltzenbein M, Slimi S, Fietz AK, et al. Increasing use of newer antiseizure medication during pregnancy: an observational study with special focus on lacosamide. Seizure.
2023;107:107–13.
684. Husein N, Langlois-Thérien T, Rioux B, etal. Medical and surgical treatment of epilepsy in
older adults: a national survey. Epilepsia. 2023;64(4):900–9.
685. Faught E, Li X, Choi J, etal. Real-world analysis of hospitalizations in patients with epilepsy
and treated with perampanel. Epilepsia Open. 2021;6(4):645–52.
686. Villanueva V, D’Souza W, Goji H, etal. PERMIT study: a global pooled analysis study
of the effectiveness and tolerability of perampanel in routine clinical practice. J Neurol.
2022;269(4):1957–77.
687. Segal E, Moretz K, Wheless J, etal. PROVE-Phase IV study of perampanel in real-world
clinical care of patients with epilepsy: interim analysis in pediatric patients. J Child Neurol.
2022;37(4):256–67.
688. Inoue Y, Sumitomo K, Matsutani K, etal. Evaluation of real-world effectiveness of perampanel in Japanese adults and older adults with epilepsy. Epileptic Disord. 2022;24(1):123–32.
689. Segal E, Wheless J, Moretz K, etal. Perampanel in real-world clinical care of adolescent and
adult patients with epilepsy: results from the retrospective Phase IV PROVE study. Seizure.
2022;98:87–94.
690. Estévez-María JC, Garamendi-Ruiz I.The real-world effectiveness and safety of perampanel
in Europe: a scoping review. Epilepsy Behav. 2022;134:108777.
691. Gasparini S, Ferlazzo E, Neri S, etal. Effectiveness of perampanel as the only add-on: retrospective, multicenter, observational real life study on epilepsy patients. Epilepsia Open.
2022;7(4):687–96.
319